Trial Profile
Korean Post-marketing Surveillance for Reyataz.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 Apr 2016 Status changed from recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 08 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.